---
title: Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
date: '2023-12-12'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38084760/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&fc=20211015124055&ff=20231213170657&v=2.18.0
source: N Engl J Med
description: 'CONCLUSIONS: The addition of subcutaneous daratumumab to VRd induction
  and consolidation therapy and to lenalidomide maintenance therapy conferred a significant
  benefit with respect to progression-free survival among transplantation-eligible
  patients with newly diagnosed multiple myeloma. (Funded by the European Myeloma
  Network in collaboration with Janssen Research and Development; PERSEUS ClinicalTrials.gov
  number, NCT03710603; EudraCT number, ...'
disable_comments: true
---
CONCLUSIONS: The addition of subcutaneous daratumumab to VRd induction and consolidation therapy and to lenalidomide maintenance therapy conferred a significant benefit with respect to progression-free survival among transplantation-eligible patients with newly diagnosed multiple myeloma. (Funded by the European Myeloma Network in collaboration with Janssen Research and Development; PERSEUS ClinicalTrials.gov number, NCT03710603; EudraCT number, ...